-
With Valeant's Continued Deterioration, Rodman & Renshaw Downgrades To Neutral
Thursday, November 10, 2016 - 10:58am | 308Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) reported its Q3 revenue and earnings short of expectations. The company’s sales could decline in 2017, partly due to competition from generic products, Rodman & Renshaw’s Raghuram Selvaraju said in a report. He downgraded the rating on...
-
Morgan Stanley Cuts Valeant's Target To $25, Admits It Got A Couple Things Wrong
Thursday, November 10, 2016 - 10:06am | 388Read More...Morgan Stanley has slashed its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares by $17 to $25, saying it underestimated generic pressures on the company's older franchises and the risk of an ex-U.S. franchise slowdown. The latest action follows Valeant’s poor third-...
-
Valeant Reveals Expanded Discounts For Its Nitropress And Isuprel
Monday, May 16, 2016 - 10:55am | 308Read More...Valeant Pharmaceuticals International, Inc. (NYSE: VRX) revealed that it would make available an enhanced rebate program to cut the prices of Nitropress, as well as, Isuprel. The move comes after a recommendation of Patient Access and Pricing Committee. The drug maker said that under the...
-
Valeant Trends Down Following Oversight Committee Release Of Docs
Tuesday, February 2, 2016 - 1:51pm | 209Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by more than 3 percent early Tuesday afternoon following the release of a memorandum from the U.S. Committee on Oversight and Government Reform. The memorandum, titled "Documents Obtained by Committee from Valeant...
-
Valeant Could See Volatile Trading, But BofA Is Still Bullish
Thursday, October 15, 2015 - 12:40pm | 410Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were lower by more than 6 percent Thursday and now down nearly 30 percent over the past three months. Valeant announced on Wednesday it has responded to government inquiries into its drug pricing practices. Sumant Kulkami of Bank of...
